Boehringer Ingelheim bags a contract manufacturer, adding muscles for cancer vaccine, oncolytic virus programs
As Boehringer Ingelheim grows its pipeline of next-gen cancer therapies, it’s also beefing up the capacity to refine and make them.
The pharma giant is snapping up Labor Dr. Merk & Kollegen, a German contract development and manufacturing organization that’s carved out a niche in virology. For Boehringer, that expertise will come in handy for the oncolytic virus and cancer vaccine programs they got from acquiring ViraTherapeutics and AMAL Therapeutics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.